Biomarker Panel Design for Clinical Trials: Building Panels That Matter

Most wellness protocols measure what is easy. At SoliVana, we measure what matters. Designing a 47-marker biomarker panel for Protocol NSR-2026 required ruthless prioritization, deep systems thinking, and a willingness to ignore what the industry considers standard.

The Problem with Standard Panels

Walk into any functional medicine clinic and you will be offered a comprehensive metabolic panel, a lipid panel, and maybe a thyroid panel. These are useful for detecting disease. They are useless for measuring recovery.

Standard panels are designed for diagnostic medicine — finding what is broken. Recovery medicine requires a different framework: finding what is improving. This demands markers that are sensitive to change, relevant to autonomic function, and interpretable within a longitudinal context.

The SoliVana Design Principles

We designed Protocol NSR-2026's panel around four core principles:

1. Autonomic Specificity

Every marker must relate — directly or indirectly — to autonomic nervous system function. If a marker does not change when autonomic state changes, it does not belong in our panel.

2. Sensitivity to Intervention

A marker that is stable regardless of intervention tells us nothing. We selected markers with high test-retest reliability that also show clinically meaningful variance in response to our protocol stack.

3. Multi-System Coverage

The autonomic nervous system regulates virtually every physiological system. Our panel spans inflammation, metabolism, endocrine function, cardiovascular health, and immune status — but always through the lens of autonomic control.

4. Non-Invasive Accessibility

We bias toward markers that can be collected through saliva, dried blood spot, or wearable devices. This enables frequent sampling without clinic visits — a requirement for longitudinal protocols.

The 47-Marker Panel

Our panel is organized into seven domains:

• Autonomic markers (6) — HRV-derived RMSSD, SDNN, LF/HF ratio, baroreflex sensitivity, respiratory sinus arrhythmia, and ECG-derived QT variability
• Inflammatory markers (5) — hs-CRP, IL-6, TNF-α, homocysteine, ferritin
• Metabolic markers (8) — fasting glucose, insulin, HbA1c, HOMA-IR, triglycerides, HDL, LDL, uric acid
• Endocrine markers (7) — cortisol awakening response (3 time points), DHEA-S, testosterone (free and total), progesterone, estradiol
• Cardiovascular markers (6) — ApoB, Lp(a), oxidized LDL, blood pressure variability, arterial stiffness index, NT-proBNP
• Nutritional markers (8) — vitamin D, B12, folate, magnesium, zinc, omega-3 index, CoQ10, glutathione
• Sleep and recovery markers (7) — sleep stage percentages, sleep latency, sleep efficiency, WASO, subjective sleep quality, recovery score, and actigraphy-derived movement index

What We Left Out

Ruthless exclusion is as important as inclusion. We deliberately omitted standard markers that are insensitive to autonomic intervention: complete blood count (CBC) without differential, basic metabolic panel (BMP), and routine urinalysis. These are disease-screening tools, not recovery-tracking instruments.

We also excluded genetic testing. SNP panels are static — they do not change with intervention. Our focus is on dynamic physiological state, not inherited predisposition.

For Research Partners

If you are designing a biomarker panel for your own protocol, start with the question: what do I need to know? Not what can I measure. What do I need to know? The answer will determine your panel — and your panel will determine whether your study produces signal or noise.